Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Related Questions
Do you routinely recommend suppressive antibiotic therapy for patients with spinal hardware infections who have undergone surgical debridement with retention of hardware?
Do you recommend the use of ampicillin/ceftriaxone for prosthetic valve endocarditis due to ampicillin-susceptible Enterococcus faecium?
How would you manage a patient with strongly suspected Lyme arthritis and negative bacterial synovial fluid cultures who was started on empiric antibiotics against typical bacterial pathogens arthritis before arthrocentesis and collection of cultures?
Would you treat Scedosporium growth in expectorated sputum in a patient with COPD, pulmonary hypertension, and bronchiectasis, who has chronic dyspnea with exertion, thick sputum production, negative bacterial cultures, and no signs of mold infection on a high resolution CT scan, with no other clinical symptoms of infection?
Under what circumstances do you recommend the chikungunya vaccine for travelers to areas without a current outbreak but with elevated risk, especially for extended stays?
How does trimethoprim-sulfamethoxazole's efficacy against S. pyogenes influence your empirical treatment of skin infections in regions with high resistance rates?
What is the recommended duration of therapy for Enterococcal bacteremia from a urinary source in patients with prosthetic valves assuming negative TEE and clearance of bacteremia?
How would you approach the management of posterior uveitis caused by Toxoplasma gondii in immunocompromised patients, considering the potential for atypical presentations and treatment resistance?
What is the best way to manage close contacts of patients with invasive group A streptococcal infections to minimize the risk of disease transmission while considering the potential adverse effects of prophylactic antibiotics?
How long do you treat Staphylococcus aureus pyomyositis with antibiotics?
